<DOC>
	<DOCNO>NCT01240486</DOCNO>
	<brief_summary>Your child able participate study , child 's doctor plan start child HAART ( combination least 3 anti HIV drug ) . When child treat HAART , way child 's body able fight infection may change . The immune system body 's defense infection . Your child 's immune system may respond strong way type infection child may already . This immune response may cause child become sick condition call `` immune reconstitution inflammatory syndrome '' IRIS .</brief_summary>
	<brief_title>IMPAACT P1073 : Study IRIS Infants Children Initiating HAART Int ' l Sites</brief_title>
	<detailed_description>IMPAACT P1073 prospective clinical , observational pathogenesis study HIV-infected infant child ART-naïve initiate HAART regimen IMPAACT study site . Where possible , infant child co-enrolled IMPAACT study give preference enrollment P1073 . The plan enroll subject P1073 timepoint ≤ 1 week prior start HAART . For DMC purpose , Step 1 P1073 , subject designate Non-case , accord Study Flow Chart</detailed_description>
	<mesh_term>Immune Reconstitution Inflammatory Syndrome</mesh_term>
	<criteria>Inclusion Criteria Past current documentation confirm diagnosis HIV1 infection . Documentation HIV1 infection define positive result two sample collect different time point . All sample test must whole blood , serum , plasma . Sample # 1 may test nonstudy public PEPFAR program . However , result assay date must record subject 's chart . Source documentation ( patient 's medical record/chart , Ministry Health ( MOH ) register , laboratory result , etc . ) must available request . Sample # 2 must perform CAP/CLIAapproved laboratory ( US sit ) laboratory operate accord GCLP guideline participate appropriate external quality assurance program ( international site ) . For P1073 , subject may enrol result Sample # 2 available . However , subject take study 2nd result negative . 1 . Acceptable test subject ≤ 18 month age 1 . Sample # 1 may test use follow : One HIV DNA PCR ; One quantitative HIV RNA PCR ( &gt; 5,000 copies/mL ) ; One qualitative HIV RNA PCR ; One total HIV nucleic acid test **If Sample # 1 positive , collect test Sample # 2 . 2 . Sample # 2 may test use assay list Sample # 1 . 2 . Acceptable test subject &gt; 18 month age 1 . Sample # 1 may test use follow : Two rapid antibody test different manufacturer base different principle epitope ; One EIA OR Western Blot OR immunofluorescence OR chemiluminescence ; One HIV DNA PCR ; One quantitative HIV RNA PCR ( &gt; 5,000 copies/mL ; One qualitative HIV RNA PCR ; One HIV culture ( prior August 2009 ) ; One total HIV nucleic acid test **If Sample # 1 positive , collect test Sample # 2 . 2 . Sample # 2 may test use follow : One EIA confirm Western Blot OR immunofluorescence OR chemiluminescence ; One HIV DNA PCR ; One quantitative HIV RNA PCR ( &gt; 5,000 copies/mL ) ; One qualitative HIV RNA PCR ; One HIV culture ( prior August 2009 ; ) One total HIV nucleic acid test Rapid antibody test allow sample # 2 Age : range ≥ 4 week &lt; 72 month age time HAART initiation . *All infant child ≥ 4 week &lt; 72 month age , initiate HAART accord National WHO criteria , eligible . HIVinfected infant child meet ART guideline local program IMPAACT protocol enrol ≤ 1 week prior start HAART . No known active untreated opportunistic infection . Infants ≤ 12 month age receive BCG immunization date BCG vaccine know . Legal guardian able willing provide sign informed consent participate IRIS study . Exclusion Criteria Any clinically significant disease ( HIV infection ) e.g . malignancy , autoimmune inflammatory disease require longterm immunosuppressive therapy , clinically significant finding screen medical history physical examination , investigator 's opinion , would compromise outcome study . Please contact team actg.teamp1073 @ fstrf.org .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>72 Months</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>IRIS</keyword>
	<keyword>HIV</keyword>
	<keyword>Immune</keyword>
	<keyword>Reconstitution</keyword>
	<keyword>Inflammatory</keyword>
	<keyword>Syndrome</keyword>
</DOC>